Brain: Risk and predictors of dementia and Parkinson's disease in the onset of fast-moving eye sleep behavior disorders

Seizure hyperactivity fast-eye sleep behavior disorder (
iRBD) is a powerful early sign of Parkinson's disease, Lu's dementia and multi-system atrophyThis provides an unprecedented opportunity to directly observe the degenerative state of precursor neurodegenerative ness, with the possibility of neuroprotective therapy interventionsFor future neuroprotective trials, it is important to accurately estimate the pint conversion rate and determine the potential predictors of the pint conversionThis study evaluated the predictors of neurodegenerative disease risk and neurodegenerative risk of a large multicenter cohortiRBDwe combine internationalThe RBDResearch Groupprospective follow-up data from 24centersAt baseline, patients withpolymyomycalwere tested for sleep, movement, cognition, autonomic nerves, and special sensations without Parkinson's disease or dementiaThe patient then underwent a prospective follow-up, during which the risk of dementia and Parkinson's disease was assessed The risk of dementia and Parkinson's disease was estimated using analysis by Kaplan-Meier The predictors of phenoconversion were assessed using Cox proportional hazard analysis and age, gender, and center correction The estimated sample size of the disease change trial was calculated using a -
event analysis Overall, , 12.8 patients were recruited The average age was 66.3 to 8.4 years old, 82.5% male The average follow-up time is 4.6 years (range - 19 years) The overall conversion rate from iRBD to dominant neurodegenerative syndrome is 6.3%/
of these, 73.5% of patients in 2012 and after follow-up 1111
years, they were transformed into dominant neurodegenerative syndrome Abnormal quantitative motion detection , objective motion check (HR-3.03) , olfactory disorder (HR-2.62) , mild cognitive impairment (HR-1 91-2.37 ), erectile dysfunction (
HR s 2.13 ), motor symptom s (
HR s 2.11 ), DAT scanning abnormalities (
HR s
1.98 ), chromatic abnormalities (
HR s
1.
69 ), constipation (
hr s 1.54 ), age (
HR s 1.54 ) Sex, daytime drowsiness, insomnia, insomnia, restlessness and leg syndrome, sleep apnea, urinary dysfunction, positive symptoms, depression, anxiety disorders, anxiety disorders, anxiety disorders, or neuro-substantive ultrasound had no significant predictive value In predictive markers, only patients with cognitive variables who converted primary dementia and Parkinson's disease at baseline time differ edgy The sample size of the deterministic neuroprotective trial sits estimated to be between 142 and 366 patients per group This large multicenter study documented high ghetto conversion rates from iRBD to dominant neurodegenerative syndrome in summary, our results provide a relative predictive value for prognostic markers that can be used to strat sedation neuroprotective trials in patients